- Home
- TCRT vs JAGX Comparison
TCRT vs JAGX Comparison
Compare TCRT & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- JAGX
- Stock Information
- Founded
- TCRT 1998
- JAGX 2013
- Country
- TCRT United States
- JAGX United States
- Employees
- TCRT N/A
- JAGX N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- JAGX Health Care
- Exchange
- TCRT Nasdaq
- JAGX Nasdaq
- Market Cap
- TCRT 3.8M
- JAGX 3.4M
- IPO Year
- TCRT N/A
- JAGX N/A
- Fundamental
- Price
- TCRT $2.74
- JAGX $1.98
- Analyst Decision
- TCRT
- JAGX Strong Buy
- Analyst Count
- TCRT 0
- JAGX 1
- Target Price
- TCRT N/A
- JAGX $60.00
- AVG Volume (30 Days)
- TCRT 58.1K
- JAGX 96.9K
- Earning Date
- TCRT 08-13-2025
- JAGX 08-12-2025
- Dividend Yield
- TCRT N/A
- JAGX N/A
- EPS Growth
- TCRT N/A
- JAGX N/A
- EPS
- TCRT N/A
- JAGX N/A
- Revenue
- TCRT $11,000.00
- JAGX $11,552,000.00
- Revenue This Year
- TCRT $5,680,500.00
- JAGX $22.41
- Revenue Next Year
- TCRT N/A
- JAGX $30.00
- P/E Ratio
- TCRT N/A
- JAGX N/A
- Revenue Growth
- TCRT 83.33
- JAGX 13.93
- 52 Week Low
- TCRT $1.31
- JAGX $1.93
- 52 Week High
- TCRT $6.20
- JAGX $35.25
- Technical
- Relative Strength Index (RSI)
- TCRT 34.42
- JAGX 23.93
- Support Level
- TCRT $2.69
- JAGX $2.19
- Resistance Level
- TCRT $3.15
- JAGX $2.79
- Average True Range (ATR)
- TCRT 0.38
- JAGX 0.10
- MACD
- TCRT -0.10
- JAGX 0.04
- Stochastic Oscillator
- TCRT 16.00
- JAGX 8.60
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.